Cost-effectiveness of gemcitabine versus PEGylated liposomal doxorubicin for recurrent or progressive ovarian cancer: Comparing chemotherapy with nanotherapy

Maria Gabriella Ferrandina, Giovanni Scambia, Rita Bosetti, Wim Marneffe, Lode Vereeck

Risultato della ricerca: Contributo in rivistaArticolo in rivista

6 Citazioni (Scopus)

Abstract

This article examines the cost-effectiveness of chemotherapy (gemcitabine) versus nanotherapy (PEGylated liposomal doxorubicin) in the treatment of ovarian cancer. Significant differences in costs were mainly due to the initial drug costs, which were €1285.28 in favor of chemotherapy. These costs were more than offset by hospitalization costs, which were €2670.21 in favor of the nanotherapy. The cost per quality-adjusted life week (QALW) for the nanotherapy was estimated to be €220.92/QALW for the base case and ranged from €170-318/QALW based on model assumptions. The clinical benefit associated with nanotherapy was achieved, yielding not only positive cost-effectiveness results, but also, surprisingly, financial savings. Although more studies are necessary, this first comprehensive analysis supports the further use of nanotherapy for ovarian cancer.
Lingua originaleEnglish
pagine (da-a)2175-2186
Numero di pagine12
RivistaNanomedicine
Volume9
Stato di pubblicazionePubblicato - 2014

Keywords

  • gemcitabine vs PEGylated
  • ovarian cancer

Fingerprint Entra nei temi di ricerca di 'Cost-effectiveness of gemcitabine versus PEGylated liposomal doxorubicin for recurrent or progressive ovarian cancer: Comparing chemotherapy with nanotherapy'. Insieme formano una fingerprint unica.

Cita questo